



(51) International Patent Classification:

A61K 31/335 (2006.01) *C07D 307/87* (2006.01)
A61K 31/395 (2006.01) *B01D 53/02* (2006.01)
A61K 31/343 (2006.01)

(21) International Application Number:

PCT/US2024/030111

(22) International Filing Date:

17 May 2024 (17.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/503,156 18 May 2023 (18.05.2023) US

(71) Applicant: **ENVEDA THERAPEUTICS, INC.** [US/US];
5700 Flatiron Parkway, Boulder, Colorado 80301 (US).(72) Inventors: **GOTTUMUKKALA, Subbaraju Venkata**; c/o Enveda Therapeutics, India, Pvt. Ltd., F. No. 502, Prayaga Residency, Pandurangapuram, AP 530003 Visakhapatnam (US). **CHERUKUPALLI, Kiran**; c/o Enveda Therapeutics, India, Pvt. Ltd., F. No. 502, Prayaga Residency, Pandurangapuram, AP 530003 Visakhapatnam (US).

NORMAN, Bryan Hurst; c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **JADHAV, Prabhakar K**; c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **KARATHANASIS, Sotirios K**; c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **MANDAL, Goutam**; c/o Enveda Therapeutics, Inc., 5700 Flatiron Parkway, Boulder, Colorado 80301 (US). **MUKHOPADHYAY, Indranil**; c/o Enveda Therapeutics, India, Pvt. Ltd., F. No. 502, Prayaga Residency, Pandurangapuram, Visakhapatnam AP 530003 (IN).

(74) Agent: **CHOI, Anita** et al.; Morrison & Foerster LLP, 425 Market Street, San Francisco, California 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: ISOANDROGRAPHOLIDE ANALOGS AND METHOD FOR TREATMENT USING THE SAME





FIG. 1A



(57) Abstract: The present disclosure relates generally to compounds, compositions, and methods for treating a variety of diseases and conditions using a therapeutically effective amount of a compound of Formula (I) or Formula (II), a pharmaceutically acceptable salt, or derivative thereof.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

06 March 2025 (06.03.2025)